Introduction
Transmissible Spongiform Encephalopathies are fatal neurodegenerative diseases that include Creutzfeldt-Jakob Disease (sCJD, vCJD) in humans, scrapie in sheep and goats and Bovine Spongiform Encephalopathy (BSE) in cattle. Prion diseases typically exhibit a lengthy latency period between the time of infection and clinical manifestation. 1 Despite substantial research on prion diseases, key issues, including the prion pathogenic mechanism and TSE transmissibility, remain elusive. Currently, there are no effective therapies for TSEs. Therefore, it is of crucial importance to identify compounds with therapeutic or prophylactic activity against these diseases.
The key event in prion pathogenesis is the structural conversion of the normal, glycolipid-anchored host prion protein, PrP C into a misfolded conformational isoform, termed PrP Sc . 2 Although PrP C is easily digested with proteinase K, the pathological form, PrP Sc , displays partial PK-resistance. Inhibition of PrP Sc formation has been a primary target for therapeutic intervention against TSEs. 3, 4 Cell lines chronically infected with TSEs have Prion diseases are fatal, neurodegenerative diseases characterized by the structural conversion of the normal, cellular prion protein, PrP c into an abnormally structured, aggregated and partially protease-resistant isoform, termed PrP sc . although substantial research has been directed toward development of therapeutics targeting prions, there is still no curative treatment for the disease. Benzoxazines are bicyclic heterocyclic compounds possessing several pharmaceutically important properties, including neuroprotection and reactive oxygen species scavenging. In an effort to identify novel inhibitors of prion formation, several 5,7,8-trimethyl-1,4-benzoxazine derivatives were evaluated in vitro for their effectiveness on the expression levels of normal PrP c and its conversion to the abnormal isoforms of PrP sc in a scrapie-infected cell culture model. The most potent compound was 2-(4-methoxyphenyl)-5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine, with a diminishing effect on the formation of PrP sc , thus establishing a class of compounds with a promising therapeutic use against prion diseases. been efficiently used to study prion-related cellular processes, 5 as well as to screen for potentially effective anti-prion compounds. Among others, chronically scrapie-infected neuroblastoma cells (ScN2a) have been used extensively as a relevant model for studying TSEs, since they are able to promote stable and persistent replication of PrP Sc , 6 upon subpassaging. Several compounds have been tested for anti-prion activity in vitro and in vivo. 7 The most effective strategies for discovering such compounds include screening for inhibitors of PrP Sc accumulation in infected cell lines, eliminating physiological PrP C as the substrate for prion conversion, and enhancing PrP Sc degradation. 8 A variety of larger molecules such as pentosan polysulfate, 9 suramin, 10 amphotericin B, 11, 12 Congo red 13 and dendritic polyamines 14 have been shown to possess antiprion properties. Among small molecules, bis-acridines, 15 polyphenols, phenothiazines, antihistamines, statins, some antimalarial agents, 16, 17 indole-3-glyoxamides, 18 pyridyl hydrazones 19 and 2-aminothiazoles 20 have been shown to inhibit PrP Sc formation in vitro. However, none of the aforementioned compounds has been proven to be effective in animal models when administered during the onset of neurological symptoms.
Inhibition of PrP
immunostaining pattern to that obtained following PK treatment of TSE-infected rodent brain homogenates (data not shown). Before assessing the influence of the derivatives on prion replication, we examined their effect on viability of the 22L scrapie N2a cells by cytometry and calculated the pertinent LD 50 (50% lethal dose) values ( (Fig. 3) . Compound TC145 was similarly tested resulting in no detectable decrease of PrP Sc accumulation (Fig. 2B) . Compounds TC128, TC143 and TC161 failed to produce a significant reduction of PrP Sc accumulation (data not shown).
In parallel, in order to determine whether PrP Sc re-accumulates after the compound is removed from the infected cultures, cells were treated with the compounds as described in the Materials and Methods section. The fifth day after subpassaging the cells were split in a ratio 1/30. Cells were grown without treatment, lysed on the fourth day and the lysates analyzed by western blot. The analysis revealed detectable levels of PrP Sc , suggesting that the effect of the studied compounds was reversible. Such a result is expected since the reduction of PrP Sc signal upon treatment with the benzoxazines, albeit high (90%) is not complete, allowing the remaining PrP Sc to drive generation of new PrP Sc molecules in the subpassaged cells.
To evaluate the effect of the tested compounds on PrP C levels, we treated uninfected N2a cells with the compounds, using the same dosage scheme. Cytometry and Protein quantification/ Densitometry were performed in order to normalize the protein levels between control and treated cells. As shown in Figure 4 , treatment of the cells with the active compounds TC121 and TC158 does not affect the PrP C levels in the N2a cells. qPCR. Real time PCR experiments demonstrate a roughly 4 fold overexpression of the PRNP gene when ScN2a cells grow in the presence of 1,4-benzoxazine derivatives TC121 and TC145 as compared with untreated cells (Fig. 5) . In contrast, treatment with compound TC158 failed to produce a significant upregulation of the PRNP transcription levels.
Real time PCR experiments were also performed in uninfected N2a cells following treatment with the benzoxazine derivatives with the same dosage scheme as ScN2a cells. In this case, there was no difference in PRNP gene expression levels between 1,4-benzoxazine-treated and untreated cells (Fig. 5) .
The 2H-1,4-benzoxazine-3-(4H)-one and 3,4-dihydro-2H-1, 4-benzoxazine derivatives have been studied extensively for their ability to act as biologically active compounds including their role as neuroprotectants. 21 Our research activities have focused on the design and synthesis of bioactive compounds possessing the 5,7,8-trimethyl-1,4-benzoxazine core which can be considered as a classical bioisostere of the 5,7,8-trimethylbenzopyran nucleus of the well-known chain-breaking antioxidant vitamin E. 22 In the course of our efforts to explore the biological properties of this class of compounds we examined six derivatives ( Fig. 1) for their effectiveness on inhibition of PrP Sc formation in mouse neuroblastoma cells (N2a) 23 permanently infected with the mouse adapted scrapie strain 22L. 2-(4-methoxyphenyl)-5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine (TC121) possesses an EC 50 of 1.17 μM and an EC 90 of 3.2 μM. Our data clearly indicate TC121 as a lead structure, capable of reducing PrP Sc concentrations in ScN2a cells, a finding of potential therapeutic relevance.
Results

Screening for PrP
Sc inhibitors. In this study we used 22L-scrapieinfected mouse neuroblastoma cells, a well-established in vitro prion disease model, to screen 5,7,8-trimethyl-1,4-benzoxazine derivatives for a potential effect on PrP C and PrP Sc levels. The structures of the compounds of the present study are shown in Figure 1 . Initially, we verified the endogenous ability of the cells to continuously convert PrP C into PrP Sc as assessed by western blot following PK digestion and we compared this PrP 
Discussion
Cultured cell lines infected with prions are widely used to study prion conversion, as well as to screen for molecules with therapeutic potential. 25 The scrapie-infected N2a assay is a valuable initial screening tool for evaluating potential drugs as numerous compounds that have been identified as PrP Sc inhibitors in these cells were subsequently shown to have at least some anti-scrapie activity in vivo. The mechanism, by which these compounds inhibit PrP Sc formation and/or enhance its clearance, remains unknown. Our data indicate that two out of six 5,7,8-trimethyl-1,4-benzoxazine derivatives tested, exert a diminishing effect on the levels of PrP Sc . More specifically, treatment of the 22L-ScN2a cells with TC121 and TC158 reduces PrP
Sc accumulation by about 90% and 50% respectively, as evaluated by western blot analysis. Conversely, the other derivatives testedhad no obvious effect on the levels of the pathological prion isoform. This effect appears to be PrP Sc -specific, since treatment of N2a cells with the same compounds produced no difference in PrP C levels between treated and untreated (control) samples.
Even though the number of compounds examined in the present study is relatively small, we can make some preliminary structure-activity relationship observations. The effect of C6 halogen substitution on the activity of the respective compounds TC145 and TC158 is worth noting. More specifically, the bromo-substituted derivative TC145 is devoid of activity against the pathological prion isoform, while switching to a chloro group on C6 renders the respective compound TC158 active. The 4-methoxyphenyl substituent at C2 confers to the corresponding derivative TC121 high anti-prion activity (EC 50 = 1.17 μM) and relatively low toxicity (LD 50 = 10 μM). Conversely, the same substituent at C3 or N4, compounds TC161 and TC128, respectively, abolishes activity. The same effect is observed for derivative TC143 which bears a 3-methoxyphenyl substituent at C3. Based on qPCR and western blot studies in N2a cells, 1,4-benzoxazine treatment does not affect PRNP gene expression, indicating that the effective compounds TC121 and TC158 do not affect the levels of the physiological PrP protein in N2a cells. However, according to qPCR experiments in ScN2a cells, TC 121 has been shown to be active at the transcriptional level as well, increasing the relative expression of the PRNP gene by a factor of 3.9 as compared with untreated cells (Fig. 5) . Similarly, TC 145 increases the mRNA levels of PrP, while the signal detected by western blot was the same as compared with control, untreated samples.
Overall, there was no correlation between the mRNA and protein data, in ScN2a cells. This is not surprising as many studies have shown that there is not always agreement between mRNA and protein levels under certain conditions. 26 Transcription and translation are not characterized by a linear relationship and different events may influence the dynamic properties of either transcription or translation into protein. Different mechanisms can repress the synthesis of proteins from a certain copy number of mRNA molecules. Many parameters may influence mRNA and protein correlation, such as regulatory proteins and RNA editing. 27 Numerous regulatory proteins can act as transcription factors. Compounds TC121 and TC145 may act directly as Different mechanisms may influence the stability of mRNA and affect translation efficiency. 27, 29 Our results indicate that TC 121 affects the PrP molecule by both major pathways, at a transcriptional and the protein processing level. Further studies concerning the mechanism of action of this derivative could focus on these two levels.
The ability of the derivatives of the present study to cross the bloodbrain barrier has not been determined experimentally, however calculation of the QP log BB using QikProp v3.4, resulted in values in the range of 95% of drugs (QPlogBB for TC121 = 0.381 for TC145 = 0.576 and for TC158 = 0.570; QPlogBB range for 95% of drugs -3.0/1.2). Therefore, they may be employed as prophylactic factors against peripheral infections. Compound TC121, 2-(4 -met hox y phenyl) -5,7,8 -trimethyl-3,4-dihydro-2H-1,4-benzoxazine represents a lead structure requiring further derivatisation to obtain more robust structure-activity relationship data, as well as, in vivo experiments in mice to further analyze the anti-prion properties of this class of compounds and to evaluate the therapeutic potential of these 5,7,8-trimethyl-1,4-benzoxazine derivatives.
Materials and Methods
Equipment and reagents. 22L-ScN2a and N2a cells that were used had been generously provided by Dr. H. Schätzl, Institute of Virology, Technical University of Munich, Germany. Handling of infectious material was performed in a safety level 2 facility.
Unless otherwise noted, all materials were obtained from commercial suppliers and used without purification. Proteinase K was purchased from Merck (1.24569.0100). All chemicals were purchased from Sigma Aldrich. Minimal essential medium (OptiMEM, 51985042), Dulbecco's phosphate-buffered saline (DPBS, 14190169), trypsin-EDTA (25200056) and Fetal Bovine Serum (FBS, 10270106) were purchased from Invitrogen-Gibco. Monoclonal anti-PrP antibody 6H4 was a generous gift from Prionics (01-011) and monoclonal anti-actin antibody β-actin (C4) was obtained from Santa Cruz Biotechnology (47778). Goat-anti-mouse IgG (Fc specific)-Peroxidase antibody was purchased from Sigma Aldrich (A0168), Alkaline Phosphatase (AP) conjugated Rabbit anti-Mouse IgG (31329) and Enhanced 
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C and allow detection of the PK-resistant PrP Sc present. For PK-treatment, cell lysates were incubated with PK (1 μg/ml) for 1 h at 37°C and then the digestion was stopped by the addition of PMSF to a final concentration of 5 mM. Finally, lauryl-sarcosyl 1% w/v was added and the proteins were methanol precipitated at -80°C for at least 2 h. Following centrifugation at 1700 g for 40 min, the protein pellets were briefly washed in 25 mM Tris (pH 8.8) containing 0.05% w/v lauryl-sarcosyl and then centrifuged at 1,700 g for 10 min. All pellets were resuspended in 2.5× O' Farrell loading buffer, boiled for 10 min, briefly centrifuged and finally analyzed by SDS-PAGE and western blotting.
Cytometry. Immediately before cell lysis, cells of each plate were checked for toxic effects, bacterial contamination and density by light microscopy. Any differences in the cells compared with controls were noted. Under the conditions of growth from low density to confluence in the presence of the tested compounds, cytotoxicity is usually obvious by light microscopy. However, cytometry was performed on a microscope Neubauer chamber following staining with trypan blue. More specifically, the fourth day post subpassaging, trypsinization of the cells Chemiluminescence (ECL, 32106) were purchased from Pierce, while CDPstar western blotting substrate was from NEB (870115). iScript cDNA synthesis kit was purchased from Biorad Laboratories (170-8890) and KAPA SYBR fast qPCR kit from KAPA Biosystems (KK4601).
Synthesis of the compounds. Compounds TC121, TC145 and TC158 were synthesized as previously reported. 30, 31 The synthesis of compounds TC143, TC158, TC161 will be reported elsewhere.
Cell culture. Cells were cultivated as previously described. 24 More specifically, 22L-ScN2a and N2a cells were cultured in Opti-MEM + (Opti-MEM, 10% FCS, 1% P/S) in 5% CO 2 at 37°C. The medium was replaced every three days and subpassaging of the cells was performed every five days for the 22L-ScN2a and every four days for the N2a cells.
Compound preparation and incubation. Compounds were diluted in dimethyl sulfoxide (DMSO), tested in several concentrations of the drug. Final DMSO concentration did not exceed 0.5% v/v and control cell cultures were treated with DMSO only, in concentrations equal to the final concentration of DMSO delivered with the compound in each plate. To minimize the effect of variables throughout the culture and subpassaging, each compound concentration was tested in duplicates in at least three independent experiments, using cells derived from different passages, covering passage 8 to passage 15. PrP Sc levels do not vary among the passages used. The compounds were administered every day for three days on equal amounts, starting on the first day after the split. TC121 was administered as following: first day, 3.33 μM; second day, 6.66 μM and third day, 3.33 μM. For TC158 the dosage scheme included: first day, 20 μM; second day, 40 μM and third day, 20 μM. These concentrations refer to the final concentration of the compounds tested in the medium. Since preliminary observations indicate that the compounds are stable in the culture conditions, concentrations of the compounds after the second administration are temporary doubled due to the protocol requirements for cell growth. This increase didn't influence the final effect as it could be judged when the titrations for efficacy and cellular toxicity performed and the medium was changed daily ( Table 1) . Cells were lysed on the fourth day after subpassaging, when, according to our pilot studies, PrP Sc levels can be detected by western blotting for the first time.
Trypsinization, lysis and proteinase K treatment. For trypsin treatment, intact cells were rinsed once in PBS and then incubated with 0.25% w/v trypsin for 2 min at room temperature. Cells growing in a 100 × 20 mm polystyrene cell culture dish (Corning Cat. Nr. 430167) were split to a ratio of 1:30 into 60 × 15 mm cell culture dishes (Corning, 430166). For lysis, they were rinsed once with PBS and then incubated with ice-cold lysis buffer, containing 10 mM Tris (pH 7.5), 100mM NaCl, 10 mM EDTA, 0.5% Triton-X-100 v/v, 0.5% sodium deoxycholate w/v, for 10 min at room temperature. The lysed cells were then centrifuged for 1 min at 14000 g to remove the cell debris. Half of each supernatant was methanol precipitated at -80°C for at least 2 h following the addition of PMSF to achieve a final concentration of 5mM. This sample was used to determine total PrP content in the cell lysate. The remaining lysate was treated with PK to digest RNA II columns. RNA elution was performed with 60 μl of RNase-free H 2 O followed by denaturation at 65°C for 5 min, according to the manufacturer's instructions. The purified RNA was quantified spectrophotometrically using Nanodrop 2000, Thermo Scientific. cDNA synthesis was performed using iScript cDNA synthesis kit with 1 μg of total RNA.
qPCR. Real-time quantitative PCR (qPCR) was performed using the KAPA SYBR fast qPCR kit. One μl of cDNA corresponding to 50 ng of total RNA was used as template for each single PCR reaction. Reliable results were obtained with a normalization factor based on three reference genes (β-actin, glyceraldehyde-3-phosphate dehydrogenase and ribosomal protein L32) and the reaction was performed in triplicates for each sample. The same experiment was repeated three times and the RNA for each experiment was isolated from cells of different subcultures. The primer sequences for the amplification of gene fragments encoding murine PrP, β-actin, glyceraldehyde-3-phosphate dehydrogenase and ribosomal protein L32 gene fragments are given in Table 2 . qPCR was performed in the 7500 Fast Real-time PCR system (Applied Biosystems). After initial denaturation for 2 min at 95°C, the following cycle was repeated 40 times: 3 sec at 95°C, 20 sec at 60°C and 30 sec at 72°C with a final extension of 3 min at 72°C. Accumulation of PCR product was monitored by measurement of SYBR Green I emission at the end of the extension step after each cycle. Melting curve analysis was performed by measuring the emission of SYBR Green I from 60°C to 95°C with a ramp rate of 1% and 10 sec hold at each temperature. PCR amplification products were visualized after separation on a 2% TBE agarose gel subsequently stained with ethidium bromide.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
was performed and 50 μl of the detached cells were diluted in equal volume of trypan blue. Ten microliters of the mixture were loaded on the Neubauer chamber and viable cells were measured using a light microscope. The trypsinized cells were then centrifuged at 1,700 g for 10 min. The pellets were resuspended in 1 ml ice-cold lysis buffer and incubated for 10 min at RT, as described in the section Trypsinization, lysis and proteinase K treatment.
The acquired values were plotted in order to determine the LD 50 values (Fig. 3) .
SDS-PAGE and antibody blotting. Protein samples were separated by SDS-PAGE on 12% w/v polyacrylamide gels. Equal loads for SDS-PAGE analysis were estimated according to the cytometry results. In the case of PK treated samples, the protein amount loaded on each well was four times higher as compared with non PK-treated samples. Proteins were then transferred to Polyvinylidene Fluoride membranes using a mini-transblot cell for 2 h at 100 V at 4°C. The PVDF membrane was blocked for 1 h at room temperature with blocking buffer [5% w/v non-fat dry milk in PBS containing 0.1% v/v Tween 20 (PBST)] and incubated overnight at 4°C with the primary antibody diluted in blocking buffer. For detection of PrP levels the monoclonal antibody used was 6H4 at a dilution 1:5,000. After washing with PBST, the membrane was incubated for 1 h at room temperature with HRP-conjugated goat anti-mouse IgG (1:10,000) and PrP was visualized on X-ray films by ECL. The same membrane was kept for estimation of actin levels and after washing with PBST for 10 min, it was incubated with β-actin (C4) antibody at 1:2,000 for 1 h. After washing with PBST, the membrane was incubated for 1 h at room temperature with AP-conjugated rabbit anti-mouse IgG at 1:10,000. Finally, the membrane was developed with CDP-star and exposed to X-ray films, as specified by the manufacturer.
Protein quantification/densitometry. Normalization of protein levels was performed based on actin levels. Protein content was estimated densitometrically using ImageJ software (version 1.37v, available at http://rsb.info.nih.gov/ij/) through the analysis of multiple film exposures to ensure that comparisons were made within the linear range of the film.
RNA isolation. Total RNA was isolated from N2a cells on the morning of the fourth day and from 22L-ScN2a cells on the evening of the fourth day post-subpassaging using Nucleospin 
